Spontaneous Adverse Event Reports of Serious Ventricular Arrhythmias,QT Prolongation,Syncope,and Sudden Death in Patients Treated with Cisapride

Abstract

Context: Adverse cardiac events, typically long QT syndrome, have been reported in patients treated with the gastrointestinal prokinetic agent cisapride.

Objective: To analyze cases of cisapride-associated long QT syndrome and ascertain the degree of confidence in the diagnosis of long QT syndrome and the presence of risk factors.

Design: Review of all cases reported to the manufacturer, health authorities, or in the medical literature as of October 1999.

Methods: Before review, specific definitions and a classification scheme were agreed upon. Each case was classified by confidence in the long QT syndrome diagnosis and the presence of recognized risk factors (cofactors) or other medical conditions that were listed as contraindications in the June 1998 United States labeling (labeled conditions).

Results: Of 574 cases reviewed, 391 cases of long QT syndrome or isolated QT prolongation were confirmed. Most of these were classified as long QT syndrome with high (145, 37%) or medium (92, 23.5%) confidence in the diagnosis. Recognized cofactors were present in 262 (67%) cases. The proportion of cases with recognized cofactors rose with confidence in the diagnosis (P < 0.001) from 42.2% in the low-confidence group to 68.5% and 82.1% in the medium- and high-confidence groups, respectively. Conversely, the proportion of cases with other labeled conditions decreased with confidence in the diagnosis, from 33.3% for low confidence to 13% and 8.3% for medium and high confidence, respectively. Analysis of cases and prescribing data showed reporting rates decreased in studied months in 1999 compared with the average study period.

Conclusion: In most cases with high or medium confidence in the diagnosis of cisapride associated long QT syndrome, recognized cofactors for long QT syndrome were present. The risk of cisapride-related long QT syndrome may be minimized by avoiding cofactors.

Keywords

long QT syndrome cisapride drug interactions

References

1. Propulsid® [package insert]. Titusville, NJ: Janssen Pharmaceutica; 2000

2. Olsson S , Edwards IR . Tachycardia during cisapride treatment. BMJ 305:748-749, 1992

3. Bran S , Murray WA , Hirsch IB , Palmer JP . Long QT syndrome during high-dose cisapride. Arch Intern Med 155:765-768, 1995

4. Lewin MB , Bryant RM , Fenrich AL , Grifka RG . Cisapride-induced long QT interval. J Pediatr 128:279-281, 1996

5. Wysowski DK , Bacsanyi J. Cisapride and fatal arrhythmia [letter]. N Engl J Med 335:290-291, 1996

6. Bedu A , Lupoglazoff JM , Faure C , Denjoy I , Casasoprana A , Aujard Y. Cisapride high dosage and long QT interval [letter; comment]. J Pediatr 130:164-164, 1997

7. Hanson R , Browne G , Fasher B , Mcaskill M , Moroney P , Hawker R. Cisapride-induced prolonged QT interval: Too much of a good thing! [letter; comment]. J Pediatr 130:164-166, 1997

8. Sekkarie MA . Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin. Am J Kidney Dis 30:437-439, 1997

9. Vitola J , Vukanovic J , Roden DM . Cisapride-induced torsades de pointes. J Cardiovasc Electrophysiol 9:1109-1113, 1998

10.

10. Ben-David J , Zipes DP . Torsades de pointes and proarrhythmia. Lancet 341:1578-1582, 1993

11.

11. Doig JC . Drug-induced cardiac arrhythmias: Incidence, prevention and management. Drug Saf 17:265-275, 1997

12.

12. Honig PK , Wortham DC , Zamani K , Conner DP , Mullin JC , Cantilena LR . Terfenadine-ketoconazole interaction: Pharmacokinetic and electrocardiographic consequences. JAMA 269:1513-1518, 1993

13.

13. Makkar RJ , Fromm BS , Steinman RT , Meissner MD , Lehman MH . Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 270; 2590-2597, 1993

14.

14. Drici MD , Knollman BC , Wang WX , Woosley RL . Cardiac actions of erythromycin: Influence of female sex. JAMA 280:1774-1776, 1998

15.

15. Hill SL , Evangelista JK , Pizzi AM , Mobassaleh M , Fulton DR , Berul CI . Proarrhythmia associated with cisapride in children. Pediatrics 101:1053-1056, 1998

16.

16. Monahan BP , Ferguson CL , Killeavy ES , Lloyd BK , Troy J , Cantilena LR . Torsades de pointes occurring in association with terfenadine use. JAMA 264:2788-2790, 1990

17.

17. Woosley RL , Chen Y , Freiman JP , Gillis RA . Mechanism of the cardiotoxic actions of terfenadine. JAMA 269:1513-1520, 1993

18.

18. Thompson D , Oster G. Use of terfenadine and contraindi cated drugs. JAMA 275:1339-1341, 1996

19.

19. Seldane and generic terfenadine withdrawn from market [FDA Talk Paper]. Rockville, Maryland, United States Food and Drug Administration, 1998

20.

20. Rampe D , Roy ML , Dennis A , Brown AM . A mechanism for the proarrhythmic effects of cisapride (Propulsid): High affinity blockade of the human cardiac potassium channel HERG. FEBS Lett 417:28-32, 1997

21.

21. Mohammad S , Zhou Z , Gong Q , January CT . Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol 273:H2534-H2538, 1997

22.

22. van Haarst AD , van't Klooster GAE , van Gerven JMA , et al. The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. Clin Pharmacol Ther 64:542-546, 1998

23.

23. Walker AM , Szneke P , Dicker LW , et al. The risk of serious cardiovascular side effects among cisapride users in the United Kingdom and Canada. Am J Med 107:356-362, 1999

24.

24. Jones JK , Fife D , Curkendalls Goehring E Jr , Gui JJ , Shannon M. Coprescribing and codispensing of cisapride and contraindicated drugs. JAMA 286:1607-1609, 2001